<SEC-DOCUMENT>0001104659-22-057365.txt : 20220509
<SEC-HEADER>0001104659-22-057365.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509125419
ACCESSION NUMBER:		0001104659-22-057365
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		22904139

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>tm2214785d2_8ka.htm
<DESCRIPTION>FORM 8-K/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20220509">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_fold_amicustherapeutics.com_20220509 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20220509_20220509 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001178879 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityCentralIndexKey">0001178879</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="fold-20220509.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-05-09to2022-05-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-09</xbrli:startDate>
        <xbrli:endDate>2022-05-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED
STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>WASHINGTON,
D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><b></b>&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20220509__20220509_zWeFBflimUll"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:DocumentType">8-K/A</ix:nonNumeric></span></b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Amendment No. 1)</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT
REPORT PURSUANT TO</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of
earliest event reported):&#160;<b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20220509__20220509_zZxUHE4Lgtwl"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 9, 2022</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20220509__20220509_z0ePiAFkU24f"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityRegistrantName">AMICUS THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Exact
Name of Registrant as Specified in  Its Charter)</p>

<p style="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center; width: 32%"><b><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20220509__20220509_zazCCzWXEX1f"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_901_edei--EntityFileNumber_c20220509__20220509_zNFSM0qaPTUb" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityFileNumber">001-33497</ix:nonNumeric></span></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20220509__20220509_zT93gzFbPL0d" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityTaxIdentificationNumber">71-0869350</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(State
                                            or Other Jurisdiction</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>of Incorporation)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(Commission</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>File Number)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(I.R.S.
                                            Employer</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>Identification No.)</b></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_905_edei--EntityAddressAddressLine1_c20220509__20220509_zNdBFsUl9DX9"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>,
<span id="xdx_90C_edei--EntityAddressCityOrTown_c20220509__20220509_zlPhBqgwzbp"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20220509__20220509_ze8FU03HgoXg"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20220509__20220509_zTcAUhkue18j"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Address of Principal
Executive Offices, and Zip Code)</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90C_edei--CityAreaCode_c20220509__20220509_zz8tpPL8iS3c"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:CityAreaCode">215</ix:nonNumeric></span>-<span id="xdx_908_edei--LocalPhoneNumber_c20220509__20220509_zHStk5TnUsIl"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:LocalPhoneNumber">921-7600</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Registrant&#8217;s
Telephone Number, Including Area Code</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report.)</p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-left: 0.5in; font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20220509__20220509_zDZoHQhl7fd6"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20220509__20220509_zq1OoFRdA513"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementTenderOffer_c20220509__20220509_z0dAyeAGVlT2"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20220509__20220509_z9Vv6cpBvwb4"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant
to Section 12(b) of the Act:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; white-space: nowrap; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><p style="margin-top: 0; margin-bottom: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Name
                                            of each exchange on which registered</span></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--Security12bTitle_c20220509__20220509_z9IvyTMzdiQk"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:Security12bTitle">Common Stock Par Value $0.01</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--TradingSymbol_c20220509__20220509_zxCXl0pkzT3k"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" name="dei:TradingSymbol">FOLD</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--SecurityExchangeName_c20220509__20220509_zT9dZvq87Und"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#167;240.12b-2). Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20220509__20220509_zGapgKXEazAj" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-05-09to2022-05-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><b>Item 2.02 Results of Operations and Financial
Condition</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">On May 9, 2022, Amicus Therapeutics, Inc. (the
&#8220;Company&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the fiscal quarter
ended March 31, 2022. A copy of this Press Release was furnished as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K (&#8220;Original
8-K&#8221;) filed with the Securities and Exchange Commission on May 9, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 27pt">The Company is furnishing this Amendment No. 1 on
Form 8-K/A (this &#8220;Amendment No. 1&#8221;) solely to correct a typographical error relating to the summary of &#8220;First Quarter
2022 Financial Results&#8221; included in the Press Release furnished with the Original 8-K. A copy of the corrected Press Release
is furnished as Exhibit 99.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 27pt">Except as specifically described above, this Amendment
No. 1 does not modify or update the Press Release or the Original  8-K, including the financial information reported therein, and
does not reflect events occurring after the dissemination of the Press Release or the filing of the Original  8-K or modify any disclosures
that may be affected by subsequent events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 27pt">In accordance with General Instruction B.2. of Form 8-K, the information
in this Current Report on Form 8-K and the Exhibits shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 29.25pt"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-indent: 2.25pt"><b>(d) Exhibits:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-indent: 2.25pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 15%; padding-top: 3.75pt; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 83%; padding-top: 3.75pt; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; padding-top: 2.75pt; padding-bottom: 1.5pt; text-align: center"><a href="tm2214785d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; text-align: justify; padding-top: 2.75pt; padding-bottom: 1.5pt"><a href="tm2214785d2_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Press Release dated May 9, 2022</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 2.75pt; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; padding-top: 3.75pt; padding-bottom: 1.5pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration: underline"><b>Signature
Page</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 27.35pt; text-indent: 0.25in">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; width: 50%"><span style="font-size: 10pt">AMICUS THERAPEUTICS, INC.</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Date: May 9, 2022</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">By: /s/ Ellen S. Rosenberg</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Name: Ellen S. Rosenberg</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Title: Chief Legal Officer and Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk0KovbRokWsIkXE19iuEmyzZRP/juQtjS3isrAsM9+MEAOR0dLUyHCcFznssWlr7REKPCOjLTE40tU6gXALvBjnWVvfvT8wpcBgYMZDeSqD0FnvxmGVgJyO5GSkZiBniVKw24joq6dkz6ZC642uQdsKdkwtG/SaX33CXj/JUvPqqg7IzpBNQA1lL78hliqGLd31g/jqIM9TEQ26iUTGdGu/NTfnqYFFjU3ocj363+gDPyxJhA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2214785d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics Announces First Quarter
2022 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>1Q22 Galafold<SUP>&reg;</SUP> Revenue Growth
of 18.5% to $78.7M</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>New Composition of Matter Patent for Galafold<SUP>&reg;
</SUP>Strengthens U.S. Patent Protection into 2038</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Advancing U.S. and EU Regulatory Reviews
and Launch Preparations for AT-GAA in Pompe Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Positive Long-Term Data from Phase 1/2 Study
of AT-GAA in Pompe Disease Presented at 2022 MDA Conference</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Conference Call and Webcast Today at 8:30
a.m. ET</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PHILADELPHIA, PA, May 9, 2022</B> &#8211;
<U>Amicus Therapeutics</U> (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing
novel medicines for rare diseases, today announced financial results for the quarter ended March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">John F. Crowley, Chairman and Chief Executive
Officer of Amicus Therapeutics, Inc., stated, &#8220;Against a tumultuous market, we at Amicus have a deeply sharpened focus. We continue
to ensure that Galafold gets to as many amenable people living with Fabry disease around the world, as seen by the significant first
quarter performance of this precision medicine. We are committed to the regulatory approvals of AT-GAA for people living with Pompe disease,
first in the United States and then in Europe and beyond. We are well on track with these anticipated approvals and the associated launch
preparations, furthering our belief in the potential for this treatment regimen to become the new global standard of care in Pompe disease.
And finally, we are laser focused on the financial strength of the business. This is anchored by the continued growth of Galafold and
the anticipated approval of AT-GAA, each with strong exclusivity well into the late 2030s. Together this uniquely positions Amicus to
deliver substantial value for shareholders and patients ahead.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Corporate Highlights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Global
revenue for Galafold<SUP>&reg;</SUP> (migalastat) in the first quarter of 2022 was $78.7 million. </B>First-quarter revenue represented
a year-over-year increase of 18.5% from total revenue of $66.4 million in the first quarter of 2021. First quarter operational revenue
growth measured at constant exchange rates (CER)<SUP>1</SUP> was 23.5%.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Galafold
U.S. intellectual property estate strengthened following the issuance of eight new patents this year, including a composition of matter
patent</B>. The Galafold U.S. intellectual property portfolio now includes 35 orange book listed patents, 19 of which provide protection
through 2038.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Long-term
Phase 1/2 data of AT-GAA presented at the 2022 MDA Clinical &amp; Scientific Conference in March. </B>Study participants treated with
AT-GAA for up to 36 months demonstrated persistent and durable effects on six-minute walk test (6MWT) distance, stability or increase
in forced vital capacity (FVC), and reductions in biomarkers of muscle damage and disease substrate.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AT-GAA
regulatory reviews progressing: </B>In the U.S., the Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA)
action date of May 29, 2022, for the New Drug Application (NDA) and July 29, 2022, for the Biologic License Application (BLA), reflective
of the two components of AT-GAA. Following a positive late cycle review meeting, the Company continues to expect the FDA to approve the
applications together by the July 29, 2022 action date. In the EU, the Committee for Medicinal Products for Human Use (CHMP) positive
opinion is expected in late 2022.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AT-GAA
launch preparations accelerating: </B>Development of pre-launch activities, targeted investments in additional personnel, and launch
inventory build are fully underway as the Company believes AT-GAA has the potential to become the new standard of care treatment regimen
for people living with Pompe disease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Multiple
expanded access programs in place driving significant enthusiasm for AT-GAA. </B>In the U.K., under the Early Access to Medicines Scheme
(EAMS) multiple physicians have requested access across all the leading Pompe centers in the country.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial
position sufficient to achieve profitability<SUP>2</SUP> in 2023. </B>Through careful management of expenses, the Company is on the path
to achieve profitability in 2023, as it executes on the global expansion of Galafold and prepares for the global launch of AT-GAA.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2022
                                            <U>Environmental, Social, and Governance (ESG) Report</U> published. </B>The Amicus ESG report
                                            highlights its dedication to patients alongside the Company&#8217;s environmental, social,
                                            and governance responsibilities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>First Quarter 2022 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
                                            revenue in the first quarter 2022 was $78.7 million, a year-over-year increase of 18.5% from
                                            total revenue of $66.4 million in the first quarter of 2021. On a constant currency basis,
                                            first quarter 2022 total revenue growth was 23.5%. Reported revenue was offset by a negative
                                            currency impact of $3.3 million, or 5.0%.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
                                            cash equivalents, and marketable securities totaled $411.2 million at March 31, 2022, compared
                                            to $482.5 million at December 31, 2021.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
                                            GAAP operating expenses of $146.5 million for the first quarter 2022 increased as compared
                                            to $112.9 million for the first quarter 2021.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
                                            non-GAAP operating expenses of $109.0 million for the first quarter of 2022 increased as
                                            compared to $90.5 million in the first quarter of 2021, reflecting manufacturing costs to
                                            support the AT-GAA launch and non-recurring expenses related to the reprioritization of the
                                            gene therapy portfolio.<SUP>3</SUP></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
                                            loss was $85.3 million, or $0.30 per share, compared to a net loss of $65.7 million, or $0.25
                                            per share, for the first quarter 2021. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2022 Financial Guidance </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            the full-year 2022, the Company anticipates total Galafold revenue of $350 million to $365
                                            million at constant exchange rates<SUP>1</SUP>. Double-digit revenue growth between 15 and
                                            20% at CER<SUP>1</SUP> in 2022 is expected to be driven by continued underlying demand from
                                            both switch and na&iuml;ve patients, geographic expansion, the continued diagnosis of new
                                            Fabry patients and commercial execution across all major markets, including the U.S., EU,
                                            U.K., and Japan. Applying average April 2022 exchange rates, the negative currency impact
                                            on full-year 2022 Galafold reported sales would be approximately 6%.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; width: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-GAAP
operating expense guidance for the full-year 2022 is $470 million to $485 million, driven by continued investment in the global Galafold
launch, AT-GAA clinical studies and pre-launch activities, in addition to certain non-recurring costs for manufacturing to support the
global launch of AT-GAA and committed obligations for the gene therapy portfolio. In 2023, Amicus expects non-GAAP operating expense
levels to come down to a similar level as in 2021.<SUP>4</SUP></FONT></TD>
</TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
                                            cash equivalents, and marketable securities totaled $411.2 million at March 31, 2022. Based
                                            on current operating models, the Company believes that the current and projected cash flows
                                            are sufficient to achieve self-sustainability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Anticipated 2022 Milestones by Program</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Galafold (migalastat) Oral Precision Medicine
for Fabry Disease</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sustain
                                            double-digit revenue growth in 2022 of $350 million to $365 million at CER</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue
                                            geographic expansion</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registry
                                            and other Phase 4 studies ongoing</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AT-GAA for Pompe Disease</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
                                            Prescription Drug User Fee Act (PDUFA) action date of May 29, 2022 for the NDA and July 29,
                                            2022 for the BLA</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">EU
                                            Committee for Medicinal Products for Human Use (CHMP) opinion expected in late 2022 </FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue
                                            to broaden early access plans in the U.K., Germany, France, Japan, and other countries</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; font-size: 10pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ongoing
                                            supportive studies, including pediatric and extension studies</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><SUP>1 </SUP>In order to illustrate
underlying performance, Amicus discusses its results in terms of constant exchange rate (CER) growth. This represents growth calculated
as if the exchange rates had remained unchanged from those used in the comparative period. Full year 2022 Galafold revenue guidance utilizes
the average actual exchange rates for 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><SUP>2 </SUP>Based on projections
of Amicus non-GAAP Net Income under current operating plans, which includes successful AT-GAA regulatory approvals and continued Galafold
growth. We define non-GAAP Net Income as GAAP Net Income excluding the impact of share-based compensation expense, changes in fair value
of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss
on extinguishment of debt, loss on impairment of assets, restructuring charges and income taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><SUP>3 </SUP>Full reconciliation of
GAAP results to the Company&#8217;s non-GAAP adjusted measures for all reporting periods appear in the tables to this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><SUP>4 </SUP>A reconciliation of the
differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high
variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call and Webcast</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">Amicus Therapeutics
will host a conference call and audio webcast today, May 9</FONT>, 2022 at 8:30 a.m. ET <FONT STYLE="color: windowtext">to discuss the
first quarter 2022 financial results and corporate updates. </FONT>Interested participants and investors may access the conference call
by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7867383.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A live audio webcast and related presentation
materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at <U>ir.amicusrx.com</U>. Web
participants are encouraged to register on the website 15 minutes prior to the start of the call. A replay of the call will be available
for seven days beginning at 11:30 a.m. ET on May 9, 2022. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406
(international); conference ID: 7867383.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><U>About Galafold</U>&nbsp;</B><BR>
Galafold<SUP>&reg;</SUP>&nbsp;(migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A)
for the treatment of Fabry disease in adults who have amenable&nbsp;galactosidase alpha gene <I>(GLA)</I>&nbsp;variants. In these patients,
Galafold works by stabilizing the body&#8217;s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally,
Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable&nbsp;<I>GLA</I>&nbsp;variants,
though amenability rates within this range vary by geography. Galafold is approved in over 40 countries around the world, including the
U.S., EU, U.K., Japan and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>U.S. INDICATIONS AND USAGE</B><BR>
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene
(<I>GLA</I>) variant based on&nbsp;<I>in&nbsp;vitro</I>&nbsp;assay data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This indication is approved under accelerated
approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for
this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>U.S. IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>ADVERSE REACTIONS</B><BR>
The most common adverse reactions reported with Galafold (&#8805;10%) were headache, nasopharyngitis, urinary tract infection, nausea
and pyrexia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>USE IN SPECIFIC POPULATIONS</B><BR>
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage.
Advise women of the potential risk to a fetus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">It is not known if Galafold is present in
human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother&#8217;s clinical
need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Galafold is not recommended for use in patients
with severe renal impairment or end-stage renal disease requiring dialysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The safety and effectiveness of Galafold
have not been established in pediatric patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">To report Suspected Adverse Reactions, contact
Amicus Therapeutics at 1-877-4AMICUS or FDA at&nbsp;1-800-FDA-1088 or&nbsp;<U>www.fda.gov/medwatch</U><FONT STYLE="color: #333333">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For additional information about Galafold,
including the full U.S. Prescribing Information, please visit&nbsp;<U>https://www.amicusrx.com/pi/Galafold.pdf</U><FONT STYLE="color: #333333">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>EU Important Safety Information</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Treatment with Galafold should be initiated and supervised by specialists
experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">Galafold
is not intended for concomitant use with enzyme replacement therapy.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="padding-top: 1pt; text-align: justify; padding-bottom: 1pt">Galafold
is not recommended for use in patients with Fabry disease who have severe renal impairment (&lt;30 mL/min/1.73 m2). The safety and efficacy
of Galafold in children less than 12 years of age have not yet been established. No data are available.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">No
dosage adjustments are required in patients with hepatic impairment or in the elderly population.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">There
is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning
to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">While
taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">Contraindications
to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">Galafold
123 mg capsules are not for children (&#8805;12 years) weighing less than 45 kg.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">It
is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients
initiated on Galafold or switched to Galafold.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">OVERDOSE:
General medical care is recommended in the case of Galafold overdose.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">The
most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For
a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD><TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="text-align: justify; padding-top: 1pt; padding-bottom: 1pt">Call
your doctor for medical advice about side effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further important safety information for Galafold, including posology
and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold
available from the EMA website at <U>www.ema.europa.eu</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Amicus Therapeutics </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus Therapeutics (Nasdaq: FOLD) is a global,
patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living
with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company&#8217;s
website at <U>www.amicusrx.com</U>, and follow on <U>Twitter</U> and <U>LinkedIn</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Non-GAAP Financial Measures </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to financial information prepared
in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management
with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect
to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as
a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does
not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may
define these measures in different ways. Full reconciliations of GAAP results to the comparable non-GAAP measures for the reported periods
appear in the financial tables section of this press release. When we provide our expectation for non-GAAP operating expenses on a forward-looking
basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available
without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded
from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have
a significant, and potentially unpredictable, impact on our future GAAP results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains
 &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995 relating to
preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and
clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans,
manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of
forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of
the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might
make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing,
and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of
preclinical studies and clinical trials, including as they are impacted by COVID-19 related disruption, are based on current
information. The potential impact on operations from the COVID-19 pandemic is inherently unknown and cannot be predicted with
confidence and may cause actual results and performance to differ materially from the statements in this release, including without
limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental
authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource
allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product. In
addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to
the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or
preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll
patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may
delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, Japan,
the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical
studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to
manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete
all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be
predictive of future results. Statements regarding corporate financial guidance and financial goals and the attainment of such
goals. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based
on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements
are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2021 and Form 10-Q for the
quarter ended March 31, 2022, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement,
and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>CONTACTS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investors: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amicus Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Andrew Faughnan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Executive Director,
Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>afaughnan@amicusrx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-3809</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Media:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amicus Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Diana Moore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Head of Global Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>dmoore@amicusrx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(609) 662-5079</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOLD-G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TABLE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net product sales</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">78,715</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">66,402</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Cost of goods sold</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,582</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,539</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross profit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">71,133</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">81,517</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">64,117</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Selling, general, and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,116</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,726</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes in fair value of contingent consideration payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">471</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,616</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,411</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,604</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">146,472</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">112,918</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(75,339</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(53,055</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other (expense) income:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">133</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,992</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,902</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before income tax</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(81,451</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(64,082</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,809</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,582</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(85,260</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(65,664</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common stockholders per common share&nbsp;&mdash; basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.30</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.25</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding&nbsp;&mdash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">288,481,741</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">264,369,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TABLE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><B>March 31,<BR>
    2022 </B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><B>December 31,<BR>
    2021 </B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">233,317</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">245,197</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Investments in marketable securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">177,878</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">237,299</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,421</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,672</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Inventories</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,324</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,818</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,960</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34,848</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">518,900</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">596,834</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-style: normal; font-size: 10pt; font-weight: normal; text-align: left">Operating lease right-of-use assets, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20,586</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, less accumulated depreciation of $20,966 and $19,882 at March 31, 2022 and December 31, 2021, respectively</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,544</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42,496</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">In-process research &amp; development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">197,797</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">197,797</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Other non-current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">25,188</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">24,427</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: right">826,938</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: right">905,140</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">22,914</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">21,513</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80,379</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">98,153</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Contingent consideration payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,151</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,900</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">7,255</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">7,409</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">129,699</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">145,975</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred reimbursements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,906</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,906</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">389,994</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">389,357</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,930</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,930</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,457</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,363</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Other non-current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">7,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">8,240</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">588,321</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">597,771</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $0.01 par value, 500,000,000 shares authorized, 280,133,856 and 278,912,800 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,809</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,808</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,617,935</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,595,419</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated other comprehensive (loss) gain:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Foreign currency translation adjustment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(420</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,251</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Unrealized loss on available-for-sale securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(608</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(270</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">(2,381,182</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black thin solid; font-size: 10pt; text-align: right">(2,295,922</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238,617</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">307,369</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: right">826,938</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black medium double; font-size: 10pt; text-align: right">905,140</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2214785d2_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TABLE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Reconciliation of Non-GAAP Financial Measures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; font-weight: bold; text-align: left"><B>Total operating expenses - as reported GAAP</B></TD><TD STYLE="width: 1%; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><B>$</B></TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><B>146,472</B></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="width: 1%; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><B>$</B></TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><B>112,918</B></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left">Research and development:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,365</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,305</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left">Selling, general and administrative:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,286</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,049</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left">Loss on impairment of assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,616</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left">Changes in fair value of contingent consideration payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,188</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">471</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,411</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,604</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expense adjustments to reported GAAP</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,490</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,429</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><B>Total operating expenses - as adjusted</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><B>108,982</B></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><B>90,489</B></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>fold-20220509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+J6bOdzZR+2YkxtmB+bZkqDyElxGo7WylFwJyGwWcJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20220509" elementFormDefault="qualified" targetNamespace="http://amicustherapeutics.com/20220509">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://amicustherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20220509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20220509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>fold-20220509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>fold-20220509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://amicustherapeutics.com/role/Cover" xlink:href="fold-20220509.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://amicustherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2214785d2_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2214785d2_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! * # 2(  A$! Q$!_\0
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M.#QQ2W&CV-U<">>V1Y.,DYP<=,CH<>]:%%',^XN6/8!P****104444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140533253909704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMICUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2214785d2_8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fold-20220509.xsd" xlink:type="simple"/>
    <context id="From2022-05-09to2022-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-05-09to2022-05-09">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-05-09to2022-05-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-05-09to2022-05-09">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-05-09to2022-05-09">2022-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-05-09to2022-05-09">AMICUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-05-09to2022-05-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-05-09to2022-05-09">001-33497</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-05-09to2022-05-09">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-05-09to2022-05-09">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-05-09to2022-05-09">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-05-09to2022-05-09">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-05-09to2022-05-09">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-05-09to2022-05-09">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-05-09to2022-05-09">921-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-05-09to2022-05-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-05-09to2022-05-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-05-09to2022-05-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-05-09to2022-05-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-05-09to2022-05-09">Common Stock Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-05-09to2022-05-09">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-05-09to2022-05-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-05-09to2022-05-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ R&:I5*K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #(9JE499!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ R&:I5)E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #(9JE4$C:7_#<$   K$   &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ R&:I5)^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #(9JE4EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #(9JE4JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ R&:I5"0>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ R&:I5&60>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2214785d2_8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://amicustherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" original="tm2214785d2_8ka.htm">tm2214785d2_8ka.htm</File>
    <File>fold-20220509.xsd</File>
    <File>fold-20220509_lab.xml</File>
    <File>fold-20220509_pre.xml</File>
    <File>tm2214785d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2214785d2_8ka.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2214785d2_8ka.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20220509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20220509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20220509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fold",
   "nsuri": "http://amicustherapeutics.com/20220509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2214785d2_8ka.htm",
      "contextRef": "From2022-05-09to2022-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://amicustherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2214785d2_8ka.htm",
      "contextRef": "From2022-05-09to2022-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-22-057365-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-057365-xbrl.zip
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MSIU%K7Q3V9HS;I9=]HQ%GAF)CC;L>1*31.0]F_[G+_+CN/Q8%%W\^]N<B='
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M.^#?SUM^XW_Y=]"Z(_\#4$L#!!0    ( ,AFJ51\B\<.FQ0   YO   3
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MKO+_T%_>3)Y=)0B[(<E-/>(EXW?MV-?+3,U/KQJI 4VT,%KL,'_]=\[I;DF
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M'G'6#7R77?8! JS\H<*NH]@:$DU.@1,"-,0W6XQ'C/C8^5$;T-GK"D!+<_Z
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MA,<Z0_HT!-C9  ".(AL5O-T=C2(#$0#6P(+ .@ X4=\.V2 0IAVB>-;X2$=
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MON9TDC]KF0%43_KT/8@9,H09;,0!:BTRQ#QR(13TC_6:P%:U0@Y**!L*'A1
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MKBYE]T?WOA3L'HG^A+&!7IQH#%S9V7?*)C>'2+T2E* 4BPA^)(%VJ#R:VE=
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M>MAGV4ER#!M8ODEZWR_58C6]!U"^ZL72KY/\&4EO2ZTK3JV'/.S/B)LF/,+
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MYT]$72@77'W(5,#0:55> )D5YZ:3.W^PXC=\KF=TT[K'X8TT)AM"KT4)\*K
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M+GAS9%!+ 0(4 Q0    ( ,AFJ53?O#W'_PH  &R'   5              "
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7;5!+!08     !0 % $H!  "Q7@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
